China Pharmahub Acquires Humanized Antibody Technology To Target China's Nascent Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- In-licensing firm China PharmaHub recently announced it is stepping into the antibody space with a joint venture targeted to bring novel humanized antibody technology to China